Nisha Pandey

Health and Me

Lancet Study Says Obesity Drug Mazdutide Shows 18% Weight Loss In 32 Weeks: How Does It Compare To Wegovy?

New Weight Loss Drug Mazdutide Shows 18% Weight Loss In 32 Weeks: How Does It Compare To Wegovy?

<span>Mazdutide</span>, an experimental weight-loss drug, could soon join the ever-expanding market of GLP-1 medications. The results from a recent clinical trial funded by <span>Eli Lilly</span> has found that mazdutide has shown an average reduction of 18.1% in body weight over 32 weeks. The trial was published in <em>The <span rel="noindex">Lancet Diabetes &amp; Endocrinology</span></em>. 

The findings have drawn attention because the experimental drug produced significant weight loss in less than eight months, establishing its position among existing medicines like <span>Wegovy</span>.

However, the findings come from a phase 2 trial involving 179 participants. Its comparison with existing players like Wegovy are yet to be done formally. 

<h2>What Did The <span rel="noindex">Mazdutide Study</span> Find?</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/ozempic-mounjaro-users-report-burning-skin-sensation-what-is-allodynia-article-156473406" data-type="tilCustomLink">Ozempic, Mounjaro Users Report Burning Skin Sensation: What Is Allodynia?</a>

Published in November 2026, the randomised, double-blind, placebo-controlled trial evaluated mazdutide in 179 overweight or obese adults with overweight but without <a href="https://www.healthandme.com/health-wellness/nick-jonas-opens-up-about-living-with-type-1-diabetes-for-more-than-2-decades-what-does-it-entail-article-156485530" data-type="tilCustomLink">type 2 diabetes</a>. 

Participants, who were recruited from 24 centres in the United States, received the once-weekly injections of different doses of the drug or a placebo. At 32 weeks, the average weight changes were:

<ul><li>Mazdutide 16 mg: 18.1% reduction in body weight</li><li>Mazdutide 10 mg: 15.6% reduction</li><li>Mazdutide 3–6 mg: 7.3% reduction</li><li>Placebo: 0.9% reduction</li></ul>

The study also reported further weight reductions by week 48, suggesting that weight loss had not reached its maximum by the primary assessment.

However, tolerability of the drug drew attention too. Gastrointestinal problems, including nausea, vomiting and diarrhoea, were among the most common side effects. 

Around 20% of participants receiving the highest 16 mg dose quit the treatment because of adverse events, primarily gastrointestinal disorders.

Also read: <a href="https://www.healthandme.com/health-wellness/australia-approves-first-glp-1-weight-loss-pill-how-it-works-who-is-eligible-article-156464346" data-type="tilCustomLink">Australia Approves First GLP-1 Weight Loss Pill: How It Works &amp; Who Is Eligible</a>

Mazdutide works differently from semaglutide, the active ingredient in <a href="https://www.healthandme.com/health-news/godzilla-drug-retatrutide-reverses-sleep-apnea-in-1-in-4-diabetes-patients-article-156425113" data-type="tilCustomLink">Ozempic</a> and Wegovy. It activates two hormone receptors involved in regulating appetite and metabolism: <span>glucagon</span>-like peptide-1 (GLP-1) and glucagon.

GLP-1 helps regulate blood sugar, which slows down emptying of the stomach and increases feelings of fullness, which can reduce food intake.

Glucagon is another hormone involved in regulating blood glucose and energy metabolism. By activating glucagon receptors along with GLP-1 receptors, mazdutide can affect energy expenditure and metabolism in addition to regulating appetite.

This dual action distinguishes it from semaglutide, which primarily targets the GLP-1 receptor.

Also read: <a href="https://www.healthandme.com/health-wellness/glp-1-drugs-may-be-more-effective-than-metformin-at-preventing-diabetes-study-article-156455262" data-type="tilCustomLink">GLP-1 Drugs May Be More Effective Than Metformin At Preventing Diabetes: Study</a>

<span>Ozempic</span> and Wegovy contain the same active ingredient, semaglutide, but have different approved uses and dosing. 

Ozempic is primarily prescribed for type 2 diabetes and certain cardiovascular and kidney conditions, while Wegovy is approved for weight management.Here is how the trial results compare:

Mazdutide 16 mg showed 18.1% weight reduction in 32 weeks. Wegovy 2.4 mg showed 14.9% in 68 weeks.  

In the STEP 1 trial, published in The <span>New England Journal of Medicine</span> in 2021, participants with overweight or obesity who received semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. Participants did not have diabetes.

Although mazdutide's 18.1% result seems higher than the 14.9% reported with <a href="https://www.healthandme.com/health-news/eli-lilly-can-continue-zepbound-ads-despite-novo-nordisks-claims-over-weight-loss-drug-comparisons-article-156412005" data-type="tilCustomLink">Wegovy</a>, the comparison has limitations. The trials differed in duration, participant characteristics, doses and study design. A direct head-to-head trial would be needed to establish which treatment produces greater weight loss.

How to Enjoy Diwali on Ozempic & Mounjaro | Doctors Share GLP-1 Diet Tips

<h2>Is Mazdutide A Promising Weight-Loss Drug?</h2>

Mazdutide has also been studied in China. In the phase 3 GLORY-2 trial, participants receiving 9 mg lost an average of 16.65% of their body weight over 60 weeks, compared to 1.50% in the placebo group. 

Its recent findings are promising but it is too early to call mazdutide more effective than existing treatments. The US study was a relatively small phase 2 trial, and its highest dose led to a high rate of discontinuation due to adverse events. Larger phase 3 trials are important to establish its long-term effectiveness, safety and tolerability.

Health Conditions A-Z

health

new-weight-loss-drug-mazdutide-shows-18-weight-loss-in-32-weeks-how-does-it-compare-to-wegovy

mazdutide

ozempic

lancet diabetes & endocrinology

eli lilly

mazdutide study

mazdutide weight loss drug

mazdutide eli lilly

wegovy

glucagon

new england journal of medicine

new-covid-19-variant-pj21-spreads-globally-who-says-symptoms-resemble-cold-flu

New COVID-19 Variant PJ.2.1 Spreads Globally: WHO Says Symptoms Resemble Cold, Flu

climate-change-is-already-harming-health-who-chief-pushes-antalya-initiative-at-cop31

Climate Change Is Already Harming Health: WHO Chief Pushes Antalya Initiative At COP31

Fitness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Mazdutide, an experimental weight-loss drug, could soon join the ever-expanding market of GLP-1 medications. The results from a recent clinical trial funded by Eli Lilly has found that mazdutide has shown an average reduction of 18.1% in body weight over 32 weeks. The trial was published in The Lancet Diabetes & Endocrinology. The findings have drawn attention because the experimental drug produced significant weight loss in less than eight months, establishing its position among existing medicines like Wegovy.However, the findings come from a phase 2 trial involving 179 participants. Its comparison with existing players like Wegovy are yet to be done formally. What Did The Mazdutide Study Find?Also read: Ozempic, Mounjaro Users Report Burning Skin Sensation: What Is Allodynia?Published in November 2026, the randomised, double-blind, placebo-controlled trial evaluated mazdutide in 179 overweight or obese adults with overweight but without type 2 diabetes. Participants, who were recruited from 24 centres in the United States, received the once-weekly injections of different doses of the drug or a placebo. At 32 weeks, the average weight changes were:Mazdutide 16 mg: 18.1% reduction in body weightMazdutide 10 mg: 15.6% reductionMazdutide 3–6 mg: 7.3% reductionPlacebo: 0.9% reductionThe study also reported further weight reductions by week 48, suggesting that weight loss had not reached its maximum by the primary assessment.However, tolerability of the drug drew attention too. Gastrointestinal problems, including nausea, vomiting and diarrhoea, were among the most common side effects. Around 20% of participants receiving the highest 16 mg dose quit the treatment because of adverse events, primarily gastrointestinal disorders.How Does Mazdutide Work?Also read: Australia Approves First GLP-1 Weight Loss Pill: How It Works & Who Is EligibleMazdutide works differently from semaglutide, the active ingredient in Ozempic and Wegovy. It activates two hormone receptors involved in regulating appetite and metabolism: glucagon-like peptide-1 (GLP-1) and glucagon.GLP-1 helps regulate blood sugar, which slows down emptying of the stomach and increases feelings of fullness, which can reduce food intake.Glucagon is another hormone involved in regulating blood glucose and energy metabolism. By activating glucagon receptors along with GLP-1 receptors, mazdutide can affect energy expenditure and metabolism in addition to regulating appetite.This dual action distinguishes it from semaglutide, which primarily targets the GLP-1 receptor.Mazdutide Vs WegovyAlso read: GLP-1 Drugs May Be More Effective Than Metformin At Preventing Diabetes: StudyOzempic and Wegovy contain the same active ingredient, semaglutide, but have different approved uses and dosing. Ozempic is primarily prescribed for type 2 diabetes and certain cardiovascular and kidney conditions, while Wegovy is approved for weight management.Here is how the trial results compare:Mazdutide 16 mg showed 18.1% weight reduction in 32 weeks. Wegovy 2.4 mg showed 14.9% in 68 weeks.  In the STEP 1 trial, published in The New England Journal of Medicine in 2021, participants with overweight or obesity who received semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. Participants did not have diabetes.Although mazdutide's 18.1% result seems higher than the 14.9% reported with Wegovy, the comparison has limitations. The trials differed in duration, participant characteristics, doses and study design. A direct head-to-head trial would be needed to establish which treatment produces greater weight loss.   Is Mazdutide A Promising Weight-Loss Drug?Mazdutide has also been studied in China. In the phase 3 GLORY-2 trial, participants receiving 9 mg lost an average of 16.65% of their body weight over 60 weeks, compared to 1.50% in the placebo group. Its recent findings are promising but it is too early to call mazdutide more effective than existing treatments. The US study was a relatively small phase 2 trial, and its highest dose led to a high rate of discontinuation due to adverse events. Larger phase 3 trials are important to establish its long-term effectiveness, safety and tolerability.

new weight loss drug mazdutide shows 18% weight loss in 32 weeks: how does it compare to wegovy?

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Lancet Study Says Obesity Drug Mazdutide Shows 18% Weight Loss In 32 Weeks: How Does It Compare To Wegovy?

Weight Loss Without Extreme Diets: What Sustainable Medical Weight Management Looks Like

Rhabdomyolysis: When An Intense Workout Can Damage Your Muscles And Harm Your Kidneys

From Rhabdomyolysis To Heart Attack: Why Marathons Can Turn Dangerous

Health Conditions A-Z